To understand the role of functional immune system in AML progression, we have used several mouse myeloid tumor models driven by MLL-AF9, RUNX1-ETO9a, ASXL1/RUNX1 mutations and ASXL1/SETBP1 mutations. This evidence concerns the gene ASXL1 and myeloid neoplasm.